Followers | 64 |
Posts | 24135 |
Boards Moderated | 0 |
Alias Born | 11/23/2016 |
![](https://investorshub.advfn.com/uicon/584660.png?cb=1599104188)
Saturday, January 18, 2020 6:29:48 AM
Initiation Date 17th January 2020, which as of writing was yesterday!
IMO it is highly unlikely that a record updated 16th Jan 2020 would deliberately forward-date trial initiation to 17th Jan 2020 if that trial in reality was initiated several months ago.
Add to that the Spanish REEC Authorisation date of 26/11/2019, only about a months and half ago, which has not been changed with this update.
Also note that the EMA record has a "Start Date*: 2019-12-05". This date is defined as:
![](http://investorshub.advfn.com/uimage/uploads/2020/1/18/jamfoEMAStartDate.png)
Furthermore, this MB has for quite some time been expecting PR announcement of the PDD trial extension, as I recall based on Missling mentioning one way back in a quarterly CC. However, it was only officially PR'ed 16th December 2019 as part of the annual Fiscal Results:
Enrollment for the Phase 2 ANAVEX®2-73 (blarcamesine) Parkinson’s disease dementia (PDD) study[4] is expected to be completed by the end of December 2019 with top-line data expected mid-2020. To offer all participants of the study access to ANAVEX®2-73 (blarcamesine), a voluntary 48-week open-label extension, including microbiome assessment, was initiated and currently 100% of eligible participants have opted into the extension study.
Or did I miss an old PR from about a year ago?
Was initiated, is a bit lax but it must mean that the CROs and patients was made aware some time before 16th Dec 2019 giving time for 100% of eligible participants to express their opt in decision.
All this just being tardy record keeping would imo required some very convincing arguments.
A) Based on all this available data, I can only concluded that the PDD OLE extension was initiated yesterday 17th January 2020!
The implication of (A) is that there will be a gap of up to almost 1 year for some patients between the end of their P2 PDD trial dosing (with any of placebo, low or high dose A2-73).
If (A) is really the case, it seems an odd situation and IMO hardly one originally created by design as Doc328 elaborated, although a bunch of very long to shorter washout periods could also be instructive.
Someone suggested the gap might have been filled by Compassionate Use of A2-73, but I very much doubt that as it would make the baseline for OLE patients quite a mess to establish. Aside from that how does the CRO and sites keep active hold of patients that finished a trial up to a year ago and then rally them all to opt in to the OLE just sometime before Dec 16th 2019?
So does the initiation of the PDD OLE signal the completion of the entire PDD P2 study? The answer to that is maybe, definitely maybe! I think if so and likely, it is simply a coincidence because usually the transition from a trial to its OLE is seamless for each patient. Waiting for all patients completing the original study creates these staggered washout periods that seems highly undesirable.
Oh well, some more open Anavex questions here hard to compute.
Lewy Body Dementia and the change of N from 120 to 150
First of all the Spanish REEC site does not mention Lewy Body Dementia at all, but it appears in the EMA record. It this a dropdown list box entry error or?
As Doc328 mentioned PDD and Lewy Body Dementia have similarities and can be hard to diagnose, at least early on. It may be that some of the enrolled patients have later been identified as having Lewy Body Dementia. This may have prompted the N increase of 30 patients as an estimate to achieve at least 120 patients with confirmed PDD.
This situation may then have presented an opportunity for the PDD OLE study to verify if A2-73 might also be effective for Lewy Body Dementia.
So either the Lewy Body thing is an EMA typo and the + 30 N represents the Australian Expansion, or Anavex got an opportunity to test A2-73 on a few Lewy Body Dementia patients in an open label setting.
PDD OLE and Titration to 50mg
Thanks to F1ash for catching that one in the REEC register.
Well that is another gap to bridge, I mean from 10mg or 20mg to 50mg is hefty titration jump. This again raises the question why such low doses to start with given that the P2a AD trial has already establish that >4ng/mL blood contraction of A2-73 is the therapeutic window and that high concentration is correlated with high dose? Guess there is a tolerability issue to deal with - not sure what else one could conclude?
PDD trial management and as for getting old in Spain
Spain has one of the highest rated health care systems in the world, despite it being a single payer tax funded one. I for one would much prefer retiring to Spain that the USA not just for healthcare reasons, but that discussion doesn't belong here.
What more is there to say or speculate on only The Flying Spaghetti Monster knows,
Recent AVXL News
- Anavex Life Sciences to Announce Fiscal 2024 Third Quarter Financial Results on Tuesday, August 6, 2024 • GlobeNewswire Inc. • 08/01/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/30/2024 09:20:53 PM
- Anavex Life Sciences Announces Translational Biomarker Data for ANAVEX®2-73 (blarcamesine) in Fragile X Syndrome (Major Cause of Autism) at the 19th NFXF International Fragile X Conference • GlobeNewswire Inc. • 07/30/2024 11:30:00 AM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 07/29/2024 09:21:49 PM
- Results from Anavex Life Sciences Landmark Phase IIb/III Trial of Blarcamesine Presented at Alzheimer's Association Conference • GlobeNewswire Inc. • 07/28/2024 09:00:00 PM
- Anavex Life Sciences to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference • GlobeNewswire Inc. • 06/20/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/17/2024 11:30:10 AM
- Anavex Life Sciences Announces Expansion of Leadership Team • GlobeNewswire Inc. • 05/22/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/17/2024 10:01:00 AM
- Anavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ • GlobeNewswire Inc. • 05/14/2024 11:30:00 AM
- Shareholders that lost money on Anavex Life Sciences Corporation(AVXL) Urged to Join Class Action - Contact The Gross Law Firm to Learn More • PR Newswire (US) • 05/10/2024 09:45:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:35:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 12:00:30 PM
- Anavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/09/2024 11:30:00 AM
- The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Anavex Life Sciences Corporation(AVXL) Shareholders • PR Newswire (US) • 05/07/2024 09:45:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/06/2024 10:03:33 AM
- Anavex Life Sciences Corporation Sued for Securities Law Violations - Contact The Gross Law Firm Before May 13, 2024 to Discuss Your Rights - AVXL • PR Newswire (US) • 05/03/2024 09:45:00 AM
- Anavex Life Sciences to Announce Fiscal 2024 Second Quarter Financial Results on Thursday, May 9th, 2024 • GlobeNewswire Inc. • 05/02/2024 11:30:00 AM
- May 13, 2024 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against AVXL • PR Newswire (US) • 04/26/2024 09:45:00 AM
- Contact The Gross Law Firm by May 13, 2024 Deadline to Join Class Action Against Anavex Life Sciences Corporation(AVXL) • PR Newswire (US) • 04/19/2024 09:45:00 AM
- The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 13, 2024 in Anavex Life Sciences Lawsuit - AVXL • PR Newswire (US) • 04/16/2024 09:45:00 AM
- Class Action Filed Against Anavex Life Sciences Corporation (AVXL) - May 13, 2024 Deadline to Join - Contact The Gross Law Firm • PR Newswire (US) • 04/12/2024 09:45:00 AM
- Anavex Life Sciences to Present at the Noble Capital Markets Virtual Healthcare Equity Conference • GlobeNewswire Inc. • 04/11/2024 11:30:00 AM
- Class Action Filed Against Anavex Life Sciences Corporation (AVXL) - May 13, 2024 Deadline to Join - Contact The Gross Law Firm • PR Newswire (US) • 04/09/2024 09:45:00 AM
Kona Gold Beverages, Inc. Announces Strategic Initiatives and Corporate Direction Changes • KGKG • Aug 2, 2024 2:00 PM
POET and Luxshare Tech Expand Product Offerings for Artificial Intelligence Networks • POET • Aug 1, 2024 9:28 AM
Management Discusses Financial Filings of Global Arena Holding Inc., for 10-K 2023 and 10-Q, 1st Quarter 2024 • GAHC • Aug 1, 2024 9:14 AM
VAYK Announces LOI to Acquire $1 Million Home Service Company to Support Airbnb Business • VAYK • Aug 1, 2024 9:00 AM
Duane Forrester Joins INDEXR as SVP of Search • MONI • Jul 31, 2024 11:46 AM
Lingerie Fighting Championships Help Fulfill Death-Bed Promise With First Major Motion Picture • BOTY • Jul 31, 2024 9:00 AM